Comparative Study of Traditional Chemotherapy and Targeted Drug Therapies in Breast Cancer

References

[1] Amjad MT, Chidharla A, Kasi A. Cancer Chemotherapy. [Updated 2023 Feb 27]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK564367/

[2] Sunilkumar MM, Finni CG, Lijimol AS, Rajagopal MR. Health-Related Suffering and Palliative Care in Breast Cancer. Curr Breast Cancer Rep. 2021;13(4):241-246. doi: 10.1007/s12609-021-00431-1. Epub 2021 Nov 16. PMID: 34804375; PMCID: PMC8593626.

[3] Nounou MI, ElAmrawy F, Ahmed N, Abdelraouf K, Goda S, Syed-Sha-Qhattal H. Breast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and Technologies. Breast Cancer (Auckl). 2015 Sep 27;9(Suppl 2):17-34. doi: 10.4137/BCBCR.S29420. PMID: 26462242; PMCID: PMC4589089.

[4] Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov. 2023 Feb;22(2):101-126. doi: 10.1038/s41573-022-00579-0. Epub 2022 Nov 7. PMID: 36344672; PMCID: PMC9640784.

[5] Slamon, D. J., Leyland-Jones, B., Shak, S., et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New England Journal of Medicine, 344(11), 783-792. https://doi.org/10.1056/NEJM200103153441101

[6] Mercogliano MF, Bruni S, Mauro FL, Schillaci R. Emerging Targeted Therapies for HER2-Positive Breast Cancer. Cancers (Basel). 2023 Mar 26;15(7):1987. doi: 10.3390/cancers15071987. PMID: 37046648; PMCID: PMC10093019.

[7] Bai YR, Yang WG, Jia R, Sun JS, Shen DD, Liu HM, Yuan S. The recent advance and prospect of poly (ADP‐ribose) polymerase inhibitors for the treatment of cancer. Medicinal Research Reviews. doi: https://doi.org/10.1002/med.22069

[8] Vikas, P., Borcherding, N., & Zhang, W. (2018). The clinical promise of immunotherapy in triple-negative breast cancer. Cancer Management and Research, 10, 6823–6833. https://doi.org/10.2147/CMAR.S185176

[9] Zhu, S., Wu, Y., Song, B. et al. Recent advances in targeted strategies for triple-negative breast cancer. J Hematol Oncol 16, 100 (2023). https://doi.org/10.1186/s13045-023-01497-3

[10] Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010 Nov 11;363(20):1938-48. doi: 10.1056/NEJMra1001389. PMID: 21067385.

[11] Angelo Di Leo, Giuseppe Curigliano, Véronique Diéras, Luca Malorni, Christos Sotiriou, Charles Swanton, Alastair Thompson, Andrew Tutt, Martine Piccart, New approaches for improving outcomes in breast cancer in Europe, The Breast, Volume 24, Issue 4, 2015, Pages 321-330, ISSN 0960-9776, doi : https://doi.org/10.1016/j.breast.2015.03.001.

[12] Buocikova, Verona, Ivan Rios-Mondragon, Eleftherios Pilalis, Aristotelis Chatziioannou, Svetlana Miklikova, Michal Mego, Karlis Pajuste, Martins Rucins, Naouale El Yamani, Eleonora Marta Longhin, and et al. 2020. "Epigenetics in Breast Cancer Therapy—New Strategies and Future Nanomedicine Perspectives" Cancers 12, no. 12: 3622. https://doi.org/10.3390/cancers12123622

[13] Alice Lee, Mustafa B.A. Djamgoz,Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies, Cancer Treatment Reviews, Volume 62, 2018, Pages 110-122, ISSN 0305-7372, https://doi.org/10.1016/j.ctrv.2017.11.003. (https://www.sciencedirect.com/science/article/pii/S0305737217301883)

[14] Wang, Yiling, and Audrey Minden. 2022. "Current Molecular Combination Therapies Used for the Treatment of Breast Cancer" International Journal of Molecular Sciences 23, no. 19: 11046. https://doi.org/10.3390/ijms231911046

[15] De Melo Gagliato, Debora, Antonio C Buzaid, Jose Manuel Perez-Garcia, Antonio Llombart, and Javier Cortes. 2020. "CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge" Cancers 12, no. 9: 2480. https://doi.org/10.3390/cancers12092480

[16] Maitland ML, Schilsky RL. Clinical trials in the era of personalized oncology. CA: a cancer journal for clinicians. 2011 Nov;61(6):365-81. https://www.nature.com/articles/nrclinonc.2011.121

@article{1706809,
      author = {Dr Uzair Vohra, Dr Darpan Agrawal, Dr Shrey Chaudhari, Dr Huma Khan},
      title = {Comparative Study of Traditional Chemotherapy and Targeted Drug Therapies in Breast Cancer},
      journal = {Iconic Research And Engineering Journals},
      year = {2024},
      volume = {8},
      number = {6},
      pages = {875-879},
      issn = {2456-8880},
      url = {https://www.irejournals.com/formatedpaper/1706809.pdf},
      abstract = {Breast cancer remains a significant global health concern, requiring diverse and effective treatment approaches. This report compares traditional chemotherapy with targeted drug therapies, focusing on their mechanisms, efficacy, side effects, and patient outcomes. Traditional chemotherapy, long a mainstay in breast cancer treatment, utilizes cytotoxic agents to kill rapidly dividing cells. While effective in reducing tumor size and improving survival, chemotherapy is non-selective, leading to widespread side effects such as nausea, hair loss, and immunosuppression, which significantly impact the patient?s quality of life. Targeted drug therapies, by contrast, represent a more precise approach by attacking specific molecular targets involved in cancer progression. These therapies, including monoclonal antibodies like trastuzumab for HER2-positive breast cancer and hormone therapies for hormone receptor-positive cancers, have significantly improved survival rates while presenting a more manageable side effect profile. For example, patients with HER2-positive breast cancer treated with trastuzumab often achieve five-year survival rates as high as 90%, compared to lower survival rates with traditional chemotherapy. The specificity of targeted therapies minimizes collateral damage to healthy cells, though some risks, like cardiac toxicity or gastrointestinal issues, remain. Additionally, emerging therapies, such as CDK4/6 inhibitors, PARP inhibitors, and immunotherapies, are offering new treatment possibilities, especially for patients with resistant or aggressive forms of breast cancer, such as triple-negative breast cancer. These therapies focus on specific molecular pathways, offering tailored treatments for complex cases and improving patient outcomes. Their integration into treatment protocols has provided additional hope for those who may not respond to traditional approaches. This comparative analysis underscores the importance of personalized medicine in breast cancer care. While traditional chemotherapy remains essential, especially in advanced or aggressive cancers, the advent of targeted therapies has shifted the treatment paradigm, offering both improved efficacy and reduced side effects. The findings highlight the need for continued research into novel therapies and combinations that can further enhance survival and quality of life for breast cancer patients. In conclusion, the study demonstrates that combining traditional and targeted therapies, guided by individual patient profiles, is key to optimizing treatment outcomes in breast cancer.},
      keywords = {Breast Cancer, Chemotherapy, Targeted Therapy, Efficacy, Safety Profile, Patient Outcomes, Personalized Medicine},
      month = {December},
  }